双膦酸盐在治疗儿童McCune-Albright综合征的应用

唐彦, 常苗苗, 杜博冉, 朱惠娟, 梅丹, 冯凯, 阳洪波, 王鸥, 邢小平

中国药学杂志 ›› 2019, Vol. 54 ›› Issue (2) : 132-136.

PDF(1096 KB)
中国药学杂志
PDF(1096 KB)
中国药学杂志 ›› 2019, Vol. 54 ›› Issue (2) : 132-136. DOI: 10.11669/cpj.2019.02.010
论著

双膦酸盐在治疗儿童McCune-Albright综合征的应用

  • 唐彦1, 常苗苗2, 杜博冉3, 朱惠娟4*, 梅丹1, 冯凯4, 阳洪波4, 王鸥4, 邢小平4
作者信息 +

Five Cases of Bisphosphonate Therapy on Children with McCune-Albright Syndrome and Literature Review

  • TANG Yan1, CHANG Miao-miao2, DU Bo-ran3, ZHU Hui-juan4*, MEI Dan1, FENG Kai4, YANG Hong-bo4, WANG Ou4, XING Xiao-ping4
Author information +
文章历史 +

摘要

目的 报告5例McCune-Albright综合征患儿应用唑来膦酸治疗骨纤维异常增殖症,为此类疾病的药物治疗提供参考。方法 对北京协和医院内分泌科收治的5例儿童McCune-Albright综合征患者应用唑来膦酸的临床资料进行总结分析,并对应用双膦酸盐治疗的有效性、安全性以及影响双膦酸盐治疗结局的因素进行文献复习。结果 双膦酸盐在儿童McCune-Albright综合征的治疗中有一定疗效,安全性较好。结论 儿童McCune-Albright综合征可应用双膦酸盐治疗骨纤维异常增殖症,骨骼受累严重程度可能影响双膦酸盐的治疗结局。

Abstract

OBJECTIVE To provide references for clinical rational drug use through five empirical analysis of zoledronate′s application on children with McCune-Albright syndrome.METHODS The clinical data of five children with McCune-Albright syndrome were analyzed and summarized. Literature review was conducted to analyze long-term out come of bisphosphonate therapy and factors influencing outcome of bisphosphonate therapy in fibrous dysplasia. RESULTS Bisphosphonate therapy achieved certain effects, and there were no serious adverse events occurred. CONCLUSION Bisphosphonate therapy can be used on children with McCune-Albright syndrome,the prognostic factor that influencing outcome of bisphosphonate therapy is the extent of skeletal involvement.

关键词

McCune-Albright综合征 / 双膦酸盐 / 儿童

Key words

McCune-Albright syndrome / bisphosphonate / children

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
唐彦, 常苗苗, 杜博冉, 朱惠娟, 梅丹, 冯凯, 阳洪波, 王鸥, 邢小平. 双膦酸盐在治疗儿童McCune-Albright综合征的应用[J]. 中国药学杂志, 2019, 54(2): 132-136 https://doi.org/10.11669/cpj.2019.02.010
TANG Yan, CHANG Miao-miao, DU Bo-ran, ZHU Hui-juan, MEI Dan, FENG Kai, YANG Hong-bo, WANG Ou, XING Xiao-ping. Five Cases of Bisphosphonate Therapy on Children with McCune-Albright Syndrome and Literature Review[J]. Chinese Pharmaceutical Journal, 2019, 54(2): 132-136 https://doi.org/10.11669/cpj.2019.02.010
中图分类号： R95   

参考文献

[1] ALBRIGHT F, BUTLER A M, HAMPTON A O, et al. Syndrome characterized by osteitis fibrosa disseminata, areas, of pigmentation, and endocrine dysfunction, with precocious puberty in females[J]. N Engl J Med, 1937, 216:727-746.
[2] LALA R, MATARAZZO P, ANDREO M. Bisphosphonate treatment of bone fibrous dysplasiain McCune-Albright syndrome[J]. J Pediatr Endocrinol Metab, 2006,19(suppl 2):583-593.
[3] TESSARIS D, MATARAZZO P, LALA R, et al. Odontoiatric perspectives and osteonecrosis of the jaw as a possible adverse effect of bisphosphonates therapy in fibrous dysplasia and McCune-Albright syndrome[J]. J Pediatr Endocrinol Metab, 2016, 29(3):333-336.
[4] WANG W B, WANG O, Pathogenesis and pharmacological treatment of fibrous dysplasia[J]. Chin J Osteoprosis Bone Miner Res(中华骨质疏松和骨矿盐疾病杂志),2014,12(4):350-356.
[5] NGAN K K, BOWE J, GOODGER N. The risk of bisphosphonate-related osteonecrosis of the jaw in children. A case report and literature review[J]. Dent Update,2013,40(9):733-734,736-738.
[6] PAPAPETROU P D. Bisphosphonate-associated adverse events[J]. Hormones,2009,8(2):96-110.
[7] GEORGE S, WEBER D R, KAPLAN P, et al. Short-term safety of zoledronic acid in young patients with bone disorders: an extensive institutional experience[J]. J Clin Endocrinol Metab, 2015,100(11):4163-4171.
[8] KUMAR C, PANIGRAHI I, SOMASEKHARAARADHYA A, et al. Zoledronate for osteogenesis imperfecta: evaluation of safety profile in children[J]. J Pediatr Endocrinol Metab,2016,29(8):947-952.
[9] MAJOOR B C, APPELMAN-DIJKSTRAN M, FIOCCO M, et al. Outcome of long-term bisphosphonate therapy in McCune-Albright syndrome and polyostotic fibrous dysplasia[J]. J Bone Miner Res,2017,32(2):264-276.
[10] BROWN J, RAMALINGAM L, ZACHARIN M. Bisphosphonate-associated osteonecrosis of the jaw:does it occur in children? [J]. Clin Endocrinol, 2008,68(6):863-867.
[11] CHAPURLAT R D, HUGUENY P, DELMAS P D, et al. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment[J]. Bone,2004,35(1):235-242.
[12] CHAN B, ZACHARIN M. Pamidronate treatment of polyostotic fibrous dysplasia: failure to prevent expansion of dysplastic lesions during childhood[J]. J Pediatr Endocrinol Metab,2006,19(1):75-80.
[13] KOS M, LUCZAK K, GODZINSKI J, et al. Treatment of monostotic fibrous dysplasia with pamidronate[J]. J Cranio-Maxillofac Surg,2004,32:10-15.
[14] PLOTKIN H, RAUCH, FZEITLIN L, et al. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone[J]. J Clin Endocrinol Metab,2003,88(16):4569-4575.
[15] AYCAN Z, ÖNDER A, ÇETINKAYA S. Eight-year follow-up of a girl with McCune-Albright syndrome[J]. J Clin Res Pediatr Endocrinol,2011,3(1):40-42.
[16] ARAGÃO A L, SILVA I N. Oral alendronate treatment for severe polyostotic fibrous dysplasia due to McCune-Albright syndrome in a child: a case report[J]. Int J Pediatr Endocrinol,2010:432060.
[17] BOYCE A M, KELLY M H, BRILLANTE B A, et al. A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone[J]. J Clin Endocrinol Metabol,2014,99(11):4133-4140.
[18] COLLINS M T, KUSHNER H, REYNOLDS J C, et al. An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone[J]. J Bone Miner Res,2005,20(2):219-226.
PDF(1096 KB)

Accesses

Citation

Detail
段落导航
相关文章

/

〈 〉